Government-Owned Inventions; Availability for Licensing, 40315-40316 [E7-14205]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 141 / Tuesday, July 24, 2007 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
mstockstill on PROD1PC66 with NOTICES
Rational HIV Therapeutic Design
Description of Technology: This
technology describes the structural
nature of a highly conserved tyrosinesulfate binding pocket on the HIV–1
gp120 envelope glycoprotein and the
use of this information to design HIVentry inhibitors that target it. The
binding pocket was characterized by
structural determinations of the Nterminus of CCR5 with gp120 as well as
of the complex of 412d (a tyrosinesulfated antibody) with gp120 and CD4.
The N terminus of CCR5, like the 412d
antibody, is tyrosine-sulfated. In spite of
structural differences between these
molecules, gp120 recognizes both
tyrosine-sulfated molecules in similar
ways, indicating that this specificity can
be exploited in the design of HIV-entry
inhibitors.
Applications: HIV therapeutic design.
Inventors: Peter D. Kwong et al.
(NIAID).
Patent Status: U.S. Provisional
Application No. 60/923,498 filed 13 Apr
2007 (HHS Reference No. E–181–2007/
0–US–01).
Licensing Contact: Susan Ano, PhD;
301/435–5515; anos@mail.nih.gov.
Collaborative Research Opportunity:
The Vaccine Research Center of the
VerDate Aug<31>2005
17:50 Jul 23, 2007
Jkt 211001
National Institute of Allergy and
Infectious Diseases as well as the
Laboratory of Bioorganic Chemistry of
the National Institute of Diabetes and
Digestive and Kidney Diseases are
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
tyrosine-sulfated CCR5-based inhibitors
of HIV–1 infection. Please contact Susan
Ano for more information.
Viral Entry or Replication Inhibitors
Description of Technology: The Tec
family of tyrosine kinases, consisting of
five family members Tec, Btk, Itk, Rlk,
and BMX, are key regulators of signaling
pathways of T lymphocytes. Many
existing antiviral therapies rely on
inhibition of viral replication, which
leads to emergence or selection of
resistant viruses. The current
technology provides an alternative
method for prevention or treatment of
viral infection through administration of
a Tec tyrosine kinase inhibitor. Such
inhibitors can be siRNA, small chemical
compounds, antisense or antibody. The
current technology describes the
inhibition of Itk (also known as Emt and
Tsk) and the resulting decrease in HIV
infectivity, replication, and
transcription for exemplary purposes.
Importantly, these inhibitors do not
affect the expression of HIV co-receptors
CCR5, CXCR4, or CD4. The current
technology could be used in
combination with therapeutics that
target virus replication.
Application: Treatment of viral
infection.
Development Status: In vitro data
available.
Inventors: Julie Readinger et al.
(NHGRI).
Patent Status: U.S. Provisional
Application No. 60/786,245 filed 29 Mar
2006 (HHS Reference No. E–151–2006/
0–US–01); PCT Application No. PCT/
US2007/007711 filed 29 Mar 2007 (HHS
Reference No. E–151–2006/1–PCT–01).
Licensing Contact: Susan Ano, Ph.D.;
301/435–5515; anos@mail.nih.gov.
Dual Expression DNA Influenza
Vaccine
Description of Technology: The NIH is
pleased to announce a single vector
DNA vaccine against influenza as
available for licensing. The single vector
expresses both hemagglutinin (HA) and
matrix (M) proteins, generating both
humoral and cellular immune
responses. The vaccine candidate
completely protected mice against
homologous virus challenge and
significantly improved survival against
heterologous virus challenge. A robust
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
40315
and reliable vaccine supply is widely
recognized as critical for seasonal or
pandemic influenza preparedness. The
advantages offered by this vaccine make
it an excellent candidate for further
development.
Advantages: (1) DNA vaccines easy to
produce and store; (2) Vaccine
candidate improved survival against
heterologous virus challenge; (3) No risk
of reversion to pathogenic strain as with
live-attenuated virus vaccines; (4) Can
be administered to immunocompromised individuals, increasing
potential market size; (5) HA and M
proteins encoded by single vector,
ensuring uniform delivery of
immunogen; (6) More efficient to boost
synergistic effects on both HA and M
specific immune responses than a
mixture of individual plasmids; (7) M
protein not subject to antigenic drift,
which allows advanced manufacturing
and overcomes the need for strain
monitoring; (8) DNA vaccines elicit
cellular immune response, essential for
efficient virus clearance.
Application: Influenza vaccine.
Inventors: Zhiping Ye et al. (CBER/
FDA).
Patent Status: U.S. Provisional
Application No. 60/786,747 filed 27 Mar
2006 (HHS Reference No. E–300–2005/
0–US–01); PCT Application No. PCT/
US2007/007529 filed 27 Mar 2007 (HHS
Reference No. E–300–2005/1–PCT–01).
Licensing Contact: Susan Ano, Ph.D.;
301/435–5515; anos@mail.nih.gov.
Collaborative Research Opportunity:
The CBER/FDA Division of Viral
Products is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the HA/M single vector
DNA vaccine. Please contact Zhiping Ye
at 301–435–5197 or
zhiping.ye@fda.hhs.gov for more
information.
Peptide Mimotope Candidates for Otitis
Media Vaccine
Description of Technology: This
technology describes peptide
mimotopes of lipooligosaccharides
(LOS) from nontypeable Haemophilus
influenzae (NTHi) and Moraxella
catarrhalis that are suitable for
developing novel vaccines against the
respective pathogens, for which there
are currently no licensed vaccines. The
mimotopes not only immunologically
mimic LOSs from NTHi and M.
catarrhalis but will also bind to
antibodies specific for the respective
LOS. NTHi and M. catarrhalis are
common pathogens that cause otitis
media in children and lower respiratory
tract infections in adults. The
E:\FR\FM\24JYN1.SGM
24JYN1
40316
Federal Register / Vol. 72, No. 141 / Tuesday, July 24, 2007 / Notices
effectiveness of a vaccine could be
increased by substitution of a LOS
epitope with a peptide mimic.
Preliminary experiments have shown
that some of the mimic peptides
conjugated to a carrier were as effective
as their respective LOS-based vaccine in
stimulating a humoral immune response
in rabbits. A single consensus amino
acid sequence was identified for M.
catarrhalis, while four such sequences
were identified for NTHi. Thus, the
identified peptides are promising
candidates for developing novel
vaccines for NTHi or M. catarrhalis.
Applications: Otitis media vaccine.
Development Status: In vivo data
available.
Inventor: Xin-Xing Gu (NIDCD).
Patent Status: U.S. Patent Application
No. 11/187,419 filed 22 Jul 2005 (HHS
Reference No. E–344–2002/0–US–03).
Licensing Contact: Susan Ano, Ph.D.;
301/435–5515; anos@mail.nih.gov.
Collaborative Research Opportunity:
The NIDCD Vaccine Research Section is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize
Peptide vaccines derived from LOS of
NTHi or M. catarrhalis. Please contact
Marianne Lynch, a technology
development specialist, at 301–594–
4094 or lynchm2@mail.nih.gov for more
information.
Dated: July 17, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–14205 Filed 7–23–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
mstockstill on PROD1PC66 with NOTICES
State-of-the-Science Conference:
Prevention of Fecal and Urinary
Incontinence in Adults; Notice
Notice is hereby given of the National
Institutes of Health (NIH) ‘‘State-of-theScience Conference: Prevention of Fecal
and Urinary Incontinence in Adults’’ to
be held December 10–12, 2007, in the
NIH Natcher Conference Center, 45
Center Drive, Bethesda, Maryland
20892. The conference will begin at 8:30
a.m. on December 10 and 11, and at 9
a.m. on December 12, and will be open
to the public.
Fecal and urinary incontinence—the
inability to control bowel movements or
urination, respectively—are conditions
with ramifications that extend well
VerDate Aug<31>2005
17:50 Jul 23, 2007
Jkt 211001
beyond their physical manifestations.
Many people find themselves
withdrawing from their social lives and
attempting to hide the problem from
their families, friends, and even their
doctors. The embarrassing nature of
these conditions poses a significant
barrier to seeking professional
treatment, resulting in a large number of
unreported, untreated individuals.
Therefore, it is difficult to determine the
accurate prevalence of these conditions,
as well as any associated medical
history trends. Incontinence is more
likely to affect the aging population,
although it is not considered a normal
consequence of aging. As baby boomers
approach their 60s, the incidence and
public health burden of incontinence
are likely to increase.
Fecal incontinence is a serious and
embarrassing problem that affects up to
5 percent of the general population and
up to 39 percent of nursing home
residents. It affects people of all ages but
is more common in women and the
elderly. Bowel function is controlled by
three factors: rectal sensation, rectal
storage capacity, and anal sphincter
pressure. If any of these are
compromised, fecal incontinence can
occur. This condition can have many
causes, including constipation, diarrhea,
complicated childbirth, muscular or
nerve damage, reduced storage capacity
due to scarring or irritation, or pelvic
dysfunction.
Although urinary incontinence can
affect people at all stages of life, it has
been estimated that urinary
incontinence affects 38 percent of
women and 17 percent of men 60 years
of age and older. Urinary incontinence
can occur if muscles in the wall of the
bladder suddenly contract or if muscles
surrounding the urethra suddenly relax.
Women who have undergone childbirth
are the most commonly associated atrisk population for urinary
incontinence. Pregnancy and delivery
can weaken pelvic muscles, and
reduced levels of the hormone estrogen
following menopause can cause reduced
muscle tone around the urethra,
increasing the chance of leakage.
Additionally, neurologic injury, birth
defects, strokes, multiple sclerosis, and
physical problems associated with aging
have been reported to contribute.
Because incontinence is likely widely
underdiagnosed and underreported, it
has been difficult to identify both at-risk
and affected populations. Also, because
the biological mechanisms that cause
both fecal and urinary incontinence are
not well understood, it has been
difficult to develop robust prevention
and management strategies. Toward that
end, the National Institute of Diabetes
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
and Digestive and Kidney Diseases and
the Office of Medical Applications of
Research of the NIH will convene a
State-of-the-Science Conference from
December 10 to 12, 2007, to assess the
available scientific evidence relevant to
the following questions:
• What are the prevalence, incidence,
and natural history of fecal and urinary
incontinence in the community and
long-term care settings?
• What is the burden of illness and
impact of fecal and urinary
incontinence on the individual and
society?
• What are the risk factors for fecal
and urinary incontinence?
• What can be done to prevent fecal
and urinary incontinence?
• What are the strategies to improve
the identification of persons at risk and
patients who have fecal and urinary
incontinence?
• What are the research priorities in
reducing the burden of illness in these
conditions?
An impartial, independent panel will
be charged with reviewing the available
published literature in advance of the
conference, including a systematic
literature review commissioned through
the Agency for Healthcare Research and
Quality. The first day and a half of the
conference will consist of presentations
by expert researchers and practitioners
and open public discussions. On
Wednesday, December 12, the panel
will present a statement of its collective
assessment of the evidence to answer
each of the questions above. The panel
will also hold a press conference to
address questions from the media. The
draft statement will be published online
later that day, and the final version will
be released approximately six weeks
later. The primary sponsors of this
meeting are the National Institute of
Diabetes and Digestive and Kidney
Diseases and the NIH Office of Medical
Applications of Research.
Advance information about the
conference and conference registration
materials may be obtained from
American Institutes for Research of
Silver Spring, Maryland, by calling 888–
644–2667, or by sending e-mail to
consensus@mail.nih.gov. American
Institutes for Research’s mailing address
is 10720 Columbia Pike, Silver Spring,
MD 20901. Registration information is
also available on the NIH Consensus
Development Program Web site at
https://consensus.nih.gov.
Please Note: The NIH has instituted
security measures to ensure the safety of NIH
employees and property. All visitors must be
prepared to show a photo ID upon request.
Visitors may be required to pass through a
metal detector and have bags, backpacks, or
E:\FR\FM\24JYN1.SGM
24JYN1
]]>Agencies
[Federal Register Volume 72, Number 141 (Tuesday, July 24, 2007)]
[Notices]
[Pages 40315-40316]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-14205]
[[Page 40315]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Rational HIV Therapeutic Design
Description of Technology: This technology describes the structural
nature of a highly conserved tyrosine-sulfate binding pocket on the
HIV-1 gp120 envelope glycoprotein and the use of this information to
design HIV-entry inhibitors that target it. The binding pocket was
characterized by structural determinations of the N-terminus of CCR5
with gp120 as well as of the complex of 412d (a tyrosine-sulfated
antibody) with gp120 and CD4. The N terminus of CCR5, like the 412d
antibody, is tyrosine-sulfated. In spite of structural differences
between these molecules, gp120 recognizes both tyrosine-sulfated
molecules in similar ways, indicating that this specificity can be
exploited in the design of HIV-entry inhibitors.
Applications: HIV therapeutic design.
Inventors: Peter D. Kwong et al. (NIAID).
Patent Status: U.S. Provisional Application No. 60/923,498 filed 13
Apr 2007 (HHS Reference No. E-181-2007/0-US-01).
Licensing Contact: Susan Ano, PhD; 301/435-5515; anos@mail.nih.gov.
Collaborative Research Opportunity: The Vaccine Research Center of
the National Institute of Allergy and Infectious Diseases as well as
the Laboratory of Bioorganic Chemistry of the National Institute of
Diabetes and Digestive and Kidney Diseases are seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize tyrosine-
sulfated CCR5-based inhibitors of HIV-1 infection. Please contact Susan
Ano for more information.
Viral Entry or Replication Inhibitors
Description of Technology: The Tec family of tyrosine kinases,
consisting of five family members Tec, Btk, Itk, Rlk, and BMX, are key
regulators of signaling pathways of T lymphocytes. Many existing
antiviral therapies rely on inhibition of viral replication, which
leads to emergence or selection of resistant viruses. The current
technology provides an alternative method for prevention or treatment
of viral infection through administration of a Tec tyrosine kinase
inhibitor. Such inhibitors can be siRNA, small chemical compounds,
antisense or antibody. The current technology describes the inhibition
of Itk (also known as Emt and Tsk) and the resulting decrease in HIV
infectivity, replication, and transcription for exemplary purposes.
Importantly, these inhibitors do not affect the expression of HIV co-
receptors CCR5, CXCR4, or CD4. The current technology could be used in
combination with therapeutics that target virus replication.
Application: Treatment of viral infection.
Development Status: In vitro data available.
Inventors: Julie Readinger et al. (NHGRI).
Patent Status: U.S. Provisional Application No. 60/786,245 filed 29
Mar 2006 (HHS Reference No. E-151-2006/0-US-01); PCT Application No.
PCT/US2007/007711 filed 29 Mar 2007 (HHS Reference No. E-151-2006/1-
PCT-01).
Licensing Contact: Susan Ano, Ph.D.; 301/435-5515;
anos@mail.nih.gov.
Dual Expression DNA Influenza Vaccine
Description of Technology: The NIH is pleased to announce a single
vector DNA vaccine against influenza as available for licensing. The
single vector expresses both hemagglutinin (HA) and matrix (M)
proteins, generating both humoral and cellular immune responses. The
vaccine candidate completely protected mice against homologous virus
challenge and significantly improved survival against heterologous
virus challenge. A robust and reliable vaccine supply is widely
recognized as critical for seasonal or pandemic influenza preparedness.
The advantages offered by this vaccine make it an excellent candidate
for further development.
Advantages: (1) DNA vaccines easy to produce and store; (2) Vaccine
candidate improved survival against heterologous virus challenge; (3)
No risk of reversion to pathogenic strain as with live-attenuated virus
vaccines; (4) Can be administered to immuno-compromised individuals,
increasing potential market size; (5) HA and M proteins encoded by
single vector, ensuring uniform delivery of immunogen; (6) More
efficient to boost synergistic effects on both HA and M specific immune
responses than a mixture of individual plasmids; (7) M protein not
subject to antigenic drift, which allows advanced manufacturing and
overcomes the need for strain monitoring; (8) DNA vaccines elicit
cellular immune response, essential for efficient virus clearance.
Application: Influenza vaccine.
Inventors: Zhiping Ye et al. (CBER/FDA).
Patent Status: U.S. Provisional Application No. 60/786,747 filed 27
Mar 2006 (HHS Reference No. E-300-2005/0-US-01); PCT Application No.
PCT/US2007/007529 filed 27 Mar 2007 (HHS Reference No. E-300-2005/1-
PCT-01).
Licensing Contact: Susan Ano, Ph.D.; 301/435-5515;
anos@mail.nih.gov.
Collaborative Research Opportunity: The CBER/FDA Division of Viral
Products is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate, or
commercialize the HA/M single vector DNA vaccine. Please contact
Zhiping Ye at 301-435-5197 or zhiping.ye@fda.hhs.gov for more
information.
Peptide Mimotope Candidates for Otitis Media Vaccine
Description of Technology: This technology describes peptide
mimotopes of lipooligosaccharides (LOS) from nontypeable Haemophilus
influenzae (NTHi) and Moraxella catarrhalis that are suitable for
developing novel vaccines against the respective pathogens, for which
there are currently no licensed vaccines. The mimotopes not only
immunologically mimic LOSs from NTHi and M. catarrhalis but will also
bind to antibodies specific for the respective LOS. NTHi and M.
catarrhalis are common pathogens that cause otitis media in children
and lower respiratory tract infections in adults. The
[[Page 40316]]
effectiveness of a vaccine could be increased by substitution of a LOS
epitope with a peptide mimic. Preliminary experiments have shown that
some of the mimic peptides conjugated to a carrier were as effective as
their respective LOS-based vaccine in stimulating a humoral immune
response in rabbits. A single consensus amino acid sequence was
identified for M. catarrhalis, while four such sequences were
identified for NTHi. Thus, the identified peptides are promising
candidates for developing novel vaccines for NTHi or M. catarrhalis.
Applications: Otitis media vaccine.
Development Status: In vivo data available.
Inventor: Xin-Xing Gu (NIDCD).
Patent Status: U.S. Patent Application No. 11/187,419 filed 22 Jul
2005 (HHS Reference No. E-344-2002/0-US-03).
Licensing Contact: Susan Ano, Ph.D.; 301/435-5515;
anos@mail.nih.gov.
Collaborative Research Opportunity: The NIDCD Vaccine Research
Section is seeking statements of capability or interest from parties
interested in collaborative research to further develop, evaluate, or
commercialize Peptide vaccines derived from LOS of NTHi or M.
catarrhalis. Please contact Marianne Lynch, a technology development
specialist, at 301-594-4094 or lynchm2@mail.nih.gov for more
information.
Dated: July 17, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-14205 Filed 7-23-07; 8:45 am]
BILLING CODE 4140-01-P
